pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Supportive Therapy

Oral Anticoagulant

  • Eg Warfarin
  • Oral anticoagulation is associated with improved survival in idiopathic pulmonary arterial hypertension (IPAH) patients & should also be considered in heritable pulmonary arterial hypertension (PAH), PAH due to anorexigen use & associated pulmonary arterial hypertension (APAH)
  • Anticoagulation in patients with PAH associated with underlying diseases such as scleroderma or congenital heart disease is controversial & one must consider risk-benefit ratio before starting Warfarin
  • Patients on long-term intravenous (IV) Epoprostenol in the absence of contraindications should be anticoagulated to prevent catheter-associated thrombosis
  • Therapeutic international normalized ratio (INR) can vary depending on the center: 1.5-2.5 or 2.0-3.0

Diuretics

  • Symptomatic & clinical benefits are seen in PAH patients with right heart failure
  • Choice & type of diuretics need to be individualized
  • Serum electrolytes & renal function should be monitored closely in those receiving diuretics

Digoxin

  • Digoxin produces favorable acute hemodynamic effects in patients with right heart failure & PAH with atrial tachyarrhythmia
    • Long-term benefits are unknown 
  • Use of Digoxin should be based on the judgment of the practitioner

Oxygen (O2) Therapy

  • Advised when oxygen saturation (SaO2) is consistently <60 mmHg to achieve SaO2 >60 mmHg for at least 15 hour/day
  • Ambulatory O2 may be given when there is improvement of symptoms & desaturation during exercise is corrected
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Feb 2017
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) during acute respiratory infection episodes may increase the risk of acute myocardial infarction (MI), a recent study from Taiwan shows.
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Pearl Toh, 01 Mar 2016
Asthma development in young children may be associated with paracetamol exposure during maternal pregnancy or infancy, a new study on the MoBa* cohort showed.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.